These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25600708)

  • 1. Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
    Hung SW; Marrache S; Cummins S; Bhutia YD; Mody H; Hooks SB; Dhar S; Govindarajan R
    Cancer Lett; 2015 Apr; 359(2):233-40. PubMed ID: 25600708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
    García-Manteiga J; Molina-Arcas M; Casado FJ; Mazo A; Pastor-Anglada M
    Clin Cancer Res; 2003 Oct; 9(13):5000-8. PubMed ID: 14581375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.
    Bhutia YD; Hung SW; Patel B; Lovin D; Govindarajan R
    Cancer Res; 2011 Mar; 71(5):1825-35. PubMed ID: 21343396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
    Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
    Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1.
    Damaraju VL; Smith KM; Mowles D; Nowak I; Karpinski E; Young JD; Robins MJ; Cass CE
    Biochem Pharmacol; 2011 Jan; 81(1):82-90. PubMed ID: 20854794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters.
    Mackey JR; Yao SY; Smith KM; Karpinski E; Baldwin SA; Cass CE; Young JD
    J Natl Cancer Inst; 1999 Nov; 91(21):1876-81. PubMed ID: 10547395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1.
    Graham KA; Leithoff J; Coe IR; Mowles D; Mackey JR; Young JD; Cass CE
    Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):415-34. PubMed ID: 10772724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
    Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
    Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
    Damaraju VL; Scriver T; Mowles D; Kuzma M; Ryan AJ; Cass CE; Sawyer MB
    Clin Cancer Res; 2014 Jan; 20(1):176-86. PubMed ID: 24170548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
    Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
    Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
    Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
    J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
    Mata JF; García-Manteiga JM; Lostao MP; Fernández-Veledo S; Guillén-Gómez E; Larrayoz IM; Lloberas J; Casado FJ; Pastor-Anglada M
    Mol Pharmacol; 2001 Jun; 59(6):1542-8. PubMed ID: 11353816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors.
    Farré X; Guillén-Gómez E; Sánchez L; Hardisson D; Plaza Y; Lloberas J; Casado FJ; Palacios J; Pastor-Anglada M
    Int J Cancer; 2004 Dec; 112(6):959-66. PubMed ID: 15386342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.
    Mackey JR; Mani RS; Selner M; Mowles D; Young JD; Belt JA; Crawford CR; Cass CE
    Cancer Res; 1998 Oct; 58(19):4349-57. PubMed ID: 9766663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes.
    Lostao MP; Mata JF; Larrayoz IM; Inzillo SM; Casado FJ; Pastor-Anglada M
    FEBS Lett; 2000 Sep; 481(2):137-40. PubMed ID: 10996312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma.
    Rose PG
    Int J Gynecol Cancer; 2005; 15 Suppl 1():18-22. PubMed ID: 15839954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy.
    Lane J; Martin TA; McGuigan C; Mason MD; Jiang WG
    J Exp Ther Oncol; 2010; 8(3):203-10. PubMed ID: 20734919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.
    Moufarij MA; Phillips DR; Cullinane C
    Mol Pharmacol; 2003 Apr; 63(4):862-9. PubMed ID: 12644587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.